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Abstract 
Consumption of foods rich in ferulic acid (FA) such as wholegrain cereals, or FA precursors such 
as chlorogenic acids in coffee, is inversely correlated with risk of cardiovascular disease and type 2 
diabetes. As a result of digestion and phase II metabolism in the gut and liver, FA is converted 
predominantly into ferulic acid-4-O-sulfate (FA-sul), an abundant plasma metabolite. Although FA-
sul may be the main metabolite, very little has been reported regarding its bioactivities. We have 
therefore compared the ex vivo vasorelaxing effect of FA and FA-sul (10-7 - 3.10-5 M) on isolated 
mouse arteries mounted in tissue myographs. FA-sul, but not FA, elicited a concentration-
dependent vasorelaxation of saphenous and femoral arteries and aortae. The FA-sul mediated 
vasorelaxation was blunted by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), a soluble 
guanylate cyclase (sGC) inhibitor. The role of sGC was confirmed in femoral arteries isolated from 
sGCα1
(-/-) knockout mice. Furthermore, 4-aminopyridine, a specific inhibitor of voltage-dependent 
potassium channels, significantly decreased FA-sul mediated effects. In anesthetized mice, 
intravenous injection of FA-sul decreased mean arterial pressure, whereas FA had no effect, 
confirming the results obtained ex vivo. FA-sul is probably one of the major metabolites accounting 
for the blood pressure-lowering effects associated with FA consumption. 
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Abbreviations 
4-AP: 4-aminopyridine, Ach: Acetylcholine, Ca2+/CaM: Ca2+/calmodulin, cGK: cGMP dependent 
protein kinase, cGMP: Cyclic guanosine monophosphate, COX: Cyclooxygenase, FA: Ferulic acid, 
FA-glu: FA-4-O-glucuronide, FA-sul: Ferulic acid-4-O-sulfate, KRB: Krebs-Ringer-Bicarbonate, Kv: 
Voltage-dependent K+-channel, L-Arg: L-arginine, L-Cit: L-citrulline, L-NAME: NG-nitro-L-arginine 
methyl ester, MAP: mean arterial pressure, NO: Nitric oxide, NOS: Nitric oxide synthase, ODQ: 1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, PDE: Phosphodiesterase, Phe: Phenylephrine, sGC: 
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soluble guanylate cyclase, SNP: Sodium Nitroprusside, TEA: Tetraethyl ammoniumchloride, 
VOCC: Voltage-operated Ca2+-channels, VSMC: Vascular smooth muscle cell. 
 
 
1: Introduction 
Polyphenols are considered to be beneficial to health, as their consumption has been inversely 
related to development of cancer, diabetes and cardiovascular diseases [1,2]. The 
hydroxycinnamic acid ferulic acid (FA) is found in rice bran, citrus fruits, banana, beetroot, spinach, 
cabbage, broccoli, tomatoes, cereals and whole grain products [3–5]. In these foods, FA is 
esterified to cell wall polysaccharides, limiting its absorption in the small intestine. In addition, 
coffee is a major source of FA in the form of chlorogenic acid esters formed between quinic acid 
and trans-cinnamic acids such as FA, p-coumaric acid and caffeic acid [6–8]. Upon arrival in the 
colon, esterase activity of the resident microflora releases FA [5], followed by conjugation to ferulic 
acid-4-O-sulfate (FA-sul) and ferulic acid-4-O-glucuronide (FA-glu) during uptake in the intestinal 
epithelium and passage through the liver [9]. Maximal total plasma FA concentrations can reach 11 
µM in rats consuming chow containing 1.5 g/kg FA for 9 days [10] and between ~290 and 800 nM 
in human volunteers upon coffee consumption [11–13]. In volunteers consuming tomatoes 
containing 21-44 mg FA, 4-5% was recovered in urine as unmodified FA, increasing to 11-25% 
when conjugated FA was included [9], comparable to 2-20% of the excreted FA present as 
glucuronide or sulfate conjugates after consumption of Pinus maritima extract [14]. When FA was 
perfused into the rat small intestine, free FA was the major form present in the mesenteric vein 
(60%), but in aorta, 75% of the FA was conjugated [15], while only conjugated FA was found in 
plasma and bile [16]. Peak plasma concentrations of FA-sul upon coffee consumption reached 
between 76 ± 9 and 226 ± 113 nM [8,17,18]. In urine, FA-sul was the predominant form of FA, 
followed by FA-glu and FA aglycone [11].  
FA consumption reduces the risk of diabetes and cardiovascular diseases, improves lipid 
metabolism [4,19,20] and decreases blood pressure in rat models of hypertension [21]. The ex vivo 
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vasorelaxant activity of FA is more pronounced in aortae isolated from hypertensive compared to 
normotensive rats [22–24]. However, the biological effects and their underlying mechanisms 
predicted by such ex vivo experiments with FA may differ from those observed in vivo, because of 
the metabolic transformation of the parent compound in the liver and during absorption in the gut 
epithelium. In this study, we have investigated the vasorelaxing effect of both the food-derived 
aglycone FA and the circulating conjugate FA-sul using mouse saphenous artery, femoral artery 
and aorta. In addition the influence of FA-sul and FA on blood pressure was measured in 
anesthetized mice.  
 
2: Materials and methods 
2.1: Animals 
Male Swiss mice were obtained from Janvier (Saint-Berthevin, France), and soluble guanylate 
cyclase (sGC) alpha 1 subunit knockout (sGCα1
(-/-)) mice and their control mice sGCα1
(+/+) with a 
129SvJ background [25] were obtained from the department of Biomedical Molecular Biology (VIB, 
Ghent, Belgium). The animals were kept in an acclimatised room and food and water were 
provided ad libitum. All animals were treated in accordance to the Guide for the Care and Use of 
Laboratory Animals published by the US National Institute of Health. This study was approved by 
the local ethical committee for animal experiments. 
 
2.2: Tissue preparation and mounting 
On the day of the experiment, animals (age 8-13 weeks) were sacrificed by cervical dislocation. 
Saphenous and femoral arteries from both legs and thoracic aorta were carefully removed and 
placed in Krebs-Ringer-Bicarbonate (KRB) solution (composition as follows (mM): NaCl, 135; KCl, 
5; NaHCO3, 20; glucose, 10; CaCl2, 2.5; MgSO4, 1.3; KH2PO4, 1.2 and EDTA, 0.026 in H2O) 
bubbled with carbogen gas (95% O2 and 5% CO2). Arteries were cleaned of surrounding 
connective and fat tissues, cut into segments and mounted in a wire myograph for isometric 
tension recording. Tissues were allowed to equilibrate for 30 minutes in KRB solution (37°C) 
bubbled with carbogen gas whilst replacing the KRB solution every 10 minutes. After equilibration, 
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isolated femoral and saphenous arteries were set to their normalised internal diameter by 
progressive stretching. The passive passive wall tension, based on internal diameter 
measurements obtained during progressive stretching, was used to adjust the arterial diameter to 
90% of the diameter the vessel would have under a transmural pressure of 100 mmHg [26]. Aortic 
rings were stretched gradually until a stable preload of 0.5 g was obtained. 
 
2.3: Experimental protocol for isometric tension recordings 
After the equilibration period (30 min) at the optimized resting tension, femoral and saphenous 
arteries were repeatedly activated by treatment with KRB solution containing 120 mM K+ and 5 µM 
phenylephrine (Phe), after which tissues were rinsed with KRB solution until a stable baseline 
tension was reached. Aortas were contracted once with KRB solution containing 120 mM K+ and 1 
µM Phe for 15 min, after which the organ baths were rinsed until a stable baseline tension was 
reached. In sGCα1
(-/-) mice femoral arteries, the efficiency of sGC was tested by cumulative 
concentration-response curves (10-9 -10-4 M) of sodium nitroprusside (SNP), a nitric oxide (NO)-
donor. In knockout mice, the response toward SNP was decreased compared to the effect in wild 
type mice, confirming effective knockout of sGC. To evaluate the presence of functional 
endothelium, arteries were exposed to 10 µM acetylcholine (Ach). Only arteries containing 
functional endothelium, as indicated by sudden relaxation upon Ach treatment, were used. Fully 
functional vessels were rinsed with KRB solution and baseline tension was maintained for 30 min 
whilst refreshing the KRB solution every 5 minutes. Arteries were contracted with Phe for 30 min 
(femoral/saphenous) or 1h (aorta) until a stable contraction was reached, after which cumulative 
concentration-response (1.10-7 - 3.10-5 M) curves for FA and FA-sul were established, exposing the 
tissues in 10 min intervals. FA-sul (90%) was synthesized by Dr. Nikolai U. Kraut (University of 
Leeds, Leeds, UK). Polyphenol stocks were prepared in a concentration of 10-2 M in 10% DMSO in 
distilled water. Appropriate dilutions of DMSO were used as control and vehicle concentrations in 
the organ baths never exceeded 0.1%. 
 
2.4: Mechanistic investigation 
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By use of specific modulators added 20 min prior to the final contraction with Phe, the mechanism 
of FA-sul mediated vasorelaxations was investigated. The NO synthase blocker NG-nitro-L-arginine 
methyl ester (L-NAME) (100 µM), cyclooxygenase (COX) inhibitor indomethacin (10 µM), sGC 
inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) (10 µM), non-specific K+-channel 
blocker tetraethyl ammoniumchloride (TEA) (3 mM), small conductance KCa-channel inhibitor 
apamin (500 nM), voltage-dependent K+-channel (Kv) inhibitor 4-aminopyridine (4-AP) (3 mM), 
inward rectifying K+-channel inhibitor Ba2+ (10 µM) and the ATP sensitive K+-channel inhibitor 
glibenclamide (3 µM) were used in this study. Glibenclamide was dissolved in DMSO; TEA, 
apamin, 4-AP, BaCl2, L-NAME in distilled water and indomethacin and ODQ in ethanol. Incubation 
with KRB solution containing 120 mM K+ and 3 mM TEA resulted in significantly higher Phe-
induced contraction levels. Endothelium was removed by gently rubbing the intimal surface with a 
stainless steel wire (aorta and femoral artery) or a hair (saphenous artery). Complete removal of 
the endothelium was verified by the lack of response toward Ach. 
 
2.5: In vivo study 
Swiss mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg) and placed on a 
heated blanked to maintain their body temperature at 37°C. A PE-10 tube filled with heparinized 
saline (25 U/mL) was inserted in the carotid artery and connected to a pressure transducer to 
measure the mean arterial pressure (MAP). The effect FA and FA-sul (standardized injection 
volume of 10 µL) on MAP was determined after injection through another PE-10 tube introduced to 
the jugular vein. Ferulic acid was dosed at 11.42 µg/kg (dose 1), and 114.2 µg/kg (dose 2). For FA-
sul, doses were 16.13 and 161.3 µg/kg respectively. Appropriate dilutions of vehicle (DMSO) 
served as controls. Treatments order (DMSO, FA, FA-sul) were randomized and tested 
sequentially in the same animal, with a total of 4 biological replicates. Between each dose, the 
cannulas were flushed four times with heparinized saline to remove residual agent. 
 
2.6: Data analysis and statistics 
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Data are represented as mean values ± S.E.M.. n represents the number of independent 
preparations in organ bath experiments or the number of mice used for in vivo experiments. For 
isometric tension measurements, data is expressed relative to the contraction level induced by Phe 
in the same preparation before cumulative addition of the compounds. In vivo, the MAP was 
determined prior to the injection of FA or FA-sul, and at the lowest point obtained after injection. 
These values were used to calculate the ∆ MAP.  
Normality of data was checked and appropriate statistical tests (Student’s t-test or Mann-Whitney 
U test) were used accordingly. *: p<0.05, **: p<0.01, ***: p<0.001. 
 
3: Results 
3.1: Response to FA and FA-sul ex vivo 
We compared the vasorelaxing properties of FA and FA-sul in mouse aorta, femoral and 
saphenous arteries. Within the concentration range tested, FA elicited no significant response. FA-
sul, however, caused significant concentration-dependent relaxations in all three tissues. The 
observed Emax was 64.2 ± 4.0% in saphenous artery, 89.8 ± 4.5% in femoral artery and 70.7 ± 
3.5% in aorta whereas in vehicle controls, tension decreased by 32.8 ± 7.4%, 14.5 ± 13.5% and -
15.9 ± 10.5% respectively (Fig. 1). Immediate relaxations were observed upon application of a 
higher concentration of FA-sul (Fig. 2).  
To exclude toxicity of FA-sul, tissues were rinsed after FA-sul treatment, maintained at basal 
resting tension for 20 minutes and contracted with Phe. The successful contraction excluded 
vasorelaxations due to tissue damage inflicted by FA-sul in our experimental setup (data not 
shown).  
 
3.3: Response to FA and FA-sul in vivo 
In Swiss mice, the basal MAP was 114.1 ± 1.7 mmHg. Immediately after intravenous injection of 
FA-sul, the MAP decreased significantly by 9.6 ± 1.2 (dose 1) and 34.9 ± 3.2 mm Hg (dose 2) (Fig. 
3 A). Intravenous injection of FA did not decrease MAP significantly compared to vehicle controls 
(Fig. 3 A). Representative traces of FA (dose 2) and FA-sul (dose 1 and 2) are presented in Fig. 3 
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B-D, showing that after a sudden decrease upon administration of FA-sul, the MAP restores to the 
original level.  
 
3.2: Vasorelaxing mechanism  
Because previous studies partly attribute FA-mediated vasorelaxation to the endothelium [22,23], 
we investigated the involvement of the endothelium in isolated aorta, femoral and saphenous 
arteries by mechanic removal and by incubation with L-NAME and indomethacin (Fig. 4). FA-sul 
induced relaxation was not attenuated by these treatments, thereby excluding the endothelium as 
an active participant in FA-sul-mediated vasorelaxation. Endothelium denudation and L-NAME 
treatment further amplified vasorelaxation upon FA-sul treatment, although the effect was only 
significant in aorta and femoral arteries respectively (Fig. 4 A,B,C,G,H,I).  
 
Even though the endothelium was not involved, a direct effect of FA-sul on sGC could not be ruled 
out and was further investigated by incubation with the sGC inhibitor ODQ (Fig. 5 A for femoral 
artery, data for aorta and saphenous artery not shown). ODQ strongly decreased FA-sul-induced 
relaxations, indicating involvement of sGC in the three arteries. The vasorelaxing effect of FA-sul 
was less pronounced in femoral arteries isolated from sGCα1
(-/-) mice compared to control mice, 
confirming sGC as a mediator of FA-sul dependent vasorelaxations (Fig. 5 B).  
 
While big arteries like aorta play a role in conducting the blood and damping pulse pressure, 
smaller arteries contribute more to arterial resistance and hence blood pressure regulation [27]. 
Consequentially, femoral or saphenous arteries provide a more relevant model for ex vivo tension 
measurements compared to large diameter arteries such as aorta. Further mechanistic 
investigations were therefore conducted only on femoral arteries where the FA-sul mediated 
relaxations were found to be maximal. Vasorelaxation pathways involving K+-channel opening 
were investigated by exposing femoral arteries to a high concentration of K+ (Fig. 6 A) or K+-
channel blockers (Fig. 6 B-F). Decreased FA-sul-induced vasorelaxation in the presence of K+ and 
TEA confirmed the involvement of K+ channels and more specifically Kv-channels, as indicated by 
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the decreased response in the presence of 4-AP (Fig. 6 A,B,F). Ba2+, apamin and glibenclamide 
did not affect FA-sul-induced relaxations (Fig. 6 C,D,E).  
 
 
4: Discussion 
We have shown for the first time that the phenolic acid conjugate FA-sul, as present in circulation 
following consumption of phenolic-rich food, is more active as an ex vivo vasorelaxant and in vivo 
blood pressure lowering compound compared to the parent aglycone FA. Since FA is a major 
phenolic present in human diet, the daily intake can exceed 100 mg [28], supporting high 
circulating FA-sul concentrations. Indeed, phase II conjugates constitute a significant portion of the 
bioavailable FA present in plasma [8,9,14,15,17,18] and urine [11,18] and could contribute to 
beneficial health effects of FA-rich foods. Although glucuronidation and sulfation generally 
decrease biological activity [29], we showed that sulfation of FA enhanced its bioactivity, a unique 
finding similar to the K+-channel-dependent vasodilatory activity of the circulating metabolite 
minoxidil sulfate, derived from the vasodilator drug minoxidil [30].  
 
To our knowledge, no other studies have determined cardiovascular health benefits of FA-sul in 
vitro, ex vivo or in vivo. Biological effects of FA on the other hand have been described. Ferulic 
acid at higher concentrations exhibits vasorelaxant properties in isolated rat arteries [22–24] and in 
vivo [21,24,31] in an endothelium-dependent fashion attributed to stimulation of NO production or 
antioxidant effects preventing NO degradation. A direct effect on vascular smooth muscle is not 
ruled out, although involvement of sGC is not confirmed [22,31,32]. The effects of FA are most 
prominent in pathophysiological conditions [21–23,31] using high concentrations of 10 µM to 30 
mM [22–24,32], which could explain the discrepancy compared to the results obtained in the 
current study where a normotensive model and lower concentrations were used.  
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By using concentrations slightly exceeding those currently reported in plasma (226 nM [17]), the 
potential of FA-sul as a blood pressure lowering compound and ex vivo vasorelaxant was 
demonstrated. The vasorelaxing mechanism of FA-sul could be investigated in more detail in 
isolated mouse arteries.  
FA-sul-induced vasorelaxation was not endothelium nor NO-dependent, as indicated by the 
unchanged relaxation in endothelium denuded arteries or upon inhibition of NOS and COX by L-
NAME and indomethacin. However, in the absence of NO, FA-sul induced relaxations were 
stimulated, and the effect reached significance in endothelium denuded aorta and L-NAME-treated 
femoral arteries. Consequentially, the potency of FA-sul was increased in the absence of NO, 
suggesting a role for FA-sul as a competitor to NO for its molecular target, sGC. Direct interactions 
between FA-sul and sGC were therefore investigated by incubation with ODQ, an sGC inhibitor 
that oxidizes the sGC heme, abolishing its NO sensitivity [33,34]. FA-sul-mediated relaxation was 
attenuated by ODQ, and the involvement of sGC in FA-sul-mediated vasodilation in Swiss mice 
was further supported by the decreased response in sGCα1
(-/-) mice femoral arteries. Catalytically 
active sGC is a heterodimeric haemoprotein consisting of α1/ß1 or α2/ß1 subunits, of which the ß1 
subunit contains the prostethic haem group [35–37]. Although the decreased response in sGCα1 
knockout mice indicates that sGC is involved, the residual activity of sGCα2ß1, whose enzymatic 
activity is substantial and unaffected in sGCα1
(-/-) mice [25], may explain the incomplete loss of 
tension in sGCα1
(-/-) mice compared to wild-type animals. These observations indicate that FA-sul 
directly activates or stimulates sGC, enhancing the generation of the second messenger cyclic 
guanosine monophosphate (cGMP) [25,34].  
Drugs that activate or stimulate sGC have been developed to treat pathologies associated with 
impaired sGC signalling. Haem-dependent sGC stimulators such as YC-1, BAY 41-2272, BAY 41-
8543, CFM 1571 and A-350619 synergistically increase sGC activity by allosteric binding in the 
presence of submaximal concentrations of NO [38,39]. In our experiments, the role of FA-sul as a 
sGC stimulator is doubtful because FA-sul caused stronger vasodilation in the absence of NO 
compared to in the presence of NO, as observed in endothelium denuded arteries or in the 
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presence of L-NAME. This suggests that FA-sul does not act as a sGC stimulator.   
sGC activators such as cinaciguat (BAY 58-2667) and HMR-1766 can increase sGC activity even 
in the absence of NO and a functional haem group in sGC [34,37]. This is of great interest since 
sGC activators are still effective when sGC has become unresponsive due to haem oxidation by 
increased oxidative stress, as is the case in diabetes, arterial hypertension, atherosclerosis and 
obesity [35,39]. Since oxidation of the ferrous haem cofactor by ODQ [34] results in almost 
complete abrogation of the effects of FA-sul, and the potency of FA-sul does not increase when the 
haem-moiety is oxidized, as is the case for most sGC activators [40], haem-independent sGC 
activator activity of FA-sul is unlikely. Our data therefore indicate that FA-sul causes a haem-
dependent activation of sGC, but further mechanistic studies are required to confirm this 
hypothesis.  
 
As a consequence of their major role in blood pressure regulation [41,42] and participation in 
downstream sGC signaling [42–44], K+-channels could be involved in the response to FA-sul. 
Nonspecific K+-channel blockade by TEA and 120 mM K+ resulted in decreased response to FA-
sul, thus confirming that FA-sul acts through K+-channel opening. By using inhibitors targeting 
specific K+-channel subtypes, we observed a decreased response in the presence of 4-AP, 
supporting Kv-channel gating as a response to FA-sul. Since sGC inhibition was very effective in 
our setup and the Kv-channels are activated in the downstream signaling cascade of sGC in rat 
arteries [45,46], indirect effects of FA-sul downstream of sGC were possible although direct 
activation of K+-channels by FA-sul could not be excluded. For example, minoxidil sulfate possibly 
acts by induction of K+-channel mediated activity through increased intracellular Ca2+, cGMP-
dependent protein kinase (cGK) mediated enhancement of KCa
+-channels sensitivity to Ca2+ [47] or 
direct sulfation of a protein subunit in K+-channels [48]. Similar mechanisms could be involved in 
the FA-sul mediated response, but they were not investigated in this study.  
The magnitude of inhibition by TEA and K+ exceeded that of 4-AP, suggesting that other potassium 
channels were involved. However, inhibition of inward rectifying, ATP-sensitive K+-channels and 
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small conductance KCa-channels by Ba
2+, glibenclamide and apamin was unsuccessful in our 
experiments, excluding them as potential mediators of FA-sul dependent vasorelaxations. 
Taken together, these data indicate that FA-sul enhances sGC activity, resulting in the production 
of cGMP and activation of its associated signaling pathways. Kv-channel opening as a 
consequence of FA-sul treatment results in K+ efflux, hyperpolarization and inhibition of voltage-
operated Ca2+-channels, decreased intracellular Ca2+ followed by vasorelaxation [32,42]. This 
pathway and the proposed role of FA-sul is summarized in Fig. 7. 
 
In conclusion, we have for the first time compared the vasorelaxing potential of FA and FA-sul in 
three types of isolated mouse arteries and in vivo in anesthetized mice and identified FA-sul as a 
potent vasorelaxing and blood pressure-lowering compound. Our data demonstrate that sGC and 
K+-channels such as voltage-gated K+-channels are involved in the FA-sul-dependent 
vasorelaxation. Therefore, phase II conjugated polyphenols such as FA-sul could be very relevant 
as mediators of the health benefits associated with consumption of FA-rich foods such as coffee or 
wholegrain products.   
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Figure 1: Vasorelaxing effects of FA-sul (left) and FA (right) (○) on isolated Swiss mouse 
saphenous artery (A,B), femoral artery (C,D) and aorta (E,F), compared to their solvent controls 
(●). Contraction (y-axis) is expressed relative to the Phe-induced contraction in the same 
preparation before cumulative addition of the compounds. Cumulative concentration-response 
curves were established between 1.10-7 and 3.10-5 M (x-axis) using 10 minute intervals. n=5. *: 
p<0.05, **: p<0.01, ***: p<0.001. 
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Figure 2. Original representative trace of the response to increasing concentrations of FA-
sul in isolated Swiss mouse femoral artery contracted with 5 µM Phe. A higher 
concentration of FA-sul is added every 10 min, as indicated by the arrows.  
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Figure 3: Effects of FA and FA-sul on blood pressure in anestetized Swiss mice.  
A: changes in mean arterial pressure (MAP, ∆ MAP = MAPafter - MAPbefore) upon intravenous 
administration of 10 µL DMSO (vehicle control, white), FA (grey) or FA-sul (black). Bars 
represent averages and S.E.M., n=4. **: p<0.01, ***: p<0.001 compared to vehicle controls. 
Original tracings obtained upon intravenous injection of FA (dose 2, B) and FA-sul (dose 1, 
C and dose 2, D) show the change in MAP in Swiss mice.  
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Figure 4: Endothelium dependency of FA-sul induced vasorelaxation in isolated Swiss 
mouse saphenous arteries (A,D,G), femoral arteries (B,E,H) and aorta (C,F,I). Vasorelaxing 
effects of FA-sul in untreated (●) or  endothelium denuded (A,B,C), indomethacin treated 
(D,E,F) or L-NAME treated (G,H,I) (○) arteries are compared. Contraction (y-axis) is 
expressed relative to the Phe-induced contraction in the same preparation before 
cumulative addition of the compounds. Cumulative concentration-response curves were 
established between 1.10-7 and 3.10-5 M (x-axis) using 10 min intervals. n=3 (L-NAME 
saphenous), n=4 (indomethacin saphenous, indomethacin aorta, L-NAME aorta) n=6 (L-
NAME femoral, endothelium denuded saphenous, endothelium denuded aorta) or n=7 
(endothelium denuded femoral, indomethacin femoral). *: p<0.05, **: p<0.01, ***: p<0.001 
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Figure 5: sGC dependency of FA-sul induced vasorelaxation in isolated femoral artery of 
Swiss (A) and sGCα1
(-/-) mice (B). Vasorelaxing effects of FA-sul (●) are compared to 
vasorelaxing activity of FA-sul in the presence of ODQ (A) in Swiss mice (○).  
Vasorelaxing effects in sGCα1
(+/+) (●) are compared to vasorelaxing activity in sGCα1
(-/-) 
mice (○) in the presence of FA-sul (B). Contraction (y-axis) is expressed relative to the Phe-
induced contraction in the same preparation before cumulative addition of the compounds. 
Cumulative concentration-response curves were established between 1.10-7 and 3.10-5 M 
(x-axis) using 10 minute intervals. n=4, *: p<0.05, **: p<0.01, ***: p<0.001. 
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Figure 6: Potassium channel dependency of FA-sul induced vasorelaxation in isolated 
Swiss mouse femoral arteries. Vasorelaxing effects of FA-sul (●) are compared to 
vasorelaxing activity of FA-sul in the presence of different K+ channel inhibitors (○): K+ (A), 
TEA (B), Ba2+ (C), apamin (D), glibenclamide (E) and 4-AP (F). Contraction (y-axis) is 
expressed relative to the Phe-induced contraction in the same preparation before 
cumulative addition of the compounds. Cumulative concentration-response curves were 
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established between 1.10-7 and 3.10-5 M (x-axis) using 10 min intervals. n=4 (Ba2+, apamin, 
glibenclamide), n=5 (120 mM K+) or n=6 (TEA, 4-AP). *: p<0.05, **: p<0.01. 
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Figure 7: Proposed mechanism of vasodilation induced by FA-sul in vascular smooth 
muscle cells (VSMC). Targets of FA-sul are indicated in red. In the endothelial cell, a 
Ca2+/Calmodulin (Ca2+/ aM) complex binds NOS, which oxidizes L-arginine (L-Arg) to L-
citrulline (L-Cit), resulting in the release of NO which diffuses out of the endothelial cell, and 
binds the FeII haem of sGC. This stimulates the conversion of GTP to cGMP and 
consequential vasodilation. FA-sul activates sGC even in the absence of NO. Ferulic acid-
sulfate mediated opening of Kv-channels results in efflux of K
+, hyperpolarization of the cell 
membrane and decreased influx of Ca2+ through voltage operated Ca2+-channels (VOCC) 
and subsequent vasodilation.  
